Medscape |
FDA Clears IV Formulation of Antifungal Posaconazole
Medscape The administration of posaconazole with sirolimus, pimozide, quinidine, atorvastatin, lovastatin, simvastatin, and ergot alkaloids “must be avoided.” When administered with posaconazole, some drugs such as cyclosporine and tacrolimus required dosage … |
|
Antiobiotics for asthma: A Madison doctor decries lack of interest in possible …
Chippewa Herald Drug companies make a lot of money from inhalers, most containing corticosteroids, which can control asthma symptoms but rarely make them go away, Hahn says. “It’s far more profitable to ‘control’ a disease than cure it,” he writes. The bacterial … |
|
Antiobiotics for asthma: A Madison doctor decries lack of interest in possible …
Madison.com Drug companies make a lot of money from inhalers, most containing corticosteroids, which can control asthma symptoms but rarely make them go away, Hahn says. “It’s far more profitable to “control” a disease than cure it,” he writes. The bacterial … |
Why Oncologists Should Study Exceptional RespondersForbesAccording to results of a new study, a patient with advanced bladder cancer experienced a complete response for 14 months to the drug combination Everolimus and Pazopanib in a Phase I trial, and …
Prednisolone eased OA knee pain by a thirdPhilippine StarPrednisolone improves pain scores in patients with moderate to severe knee osteoarthritis by nearly one-third, according to the WOMAC pain scale, compared with patients on placebo, according to a…
|
Veloxis Pharmaceuticals A/S – Correction: US FDA Accepts Veloxis’ New Drug …
Wall Street Journal Envarsus(R) is Veloxis’ once-daily tacrolimus based on the company’s proprietary MELTDOSE technology. Key points: — FDA has set a target review date under the Prescription Drug User Fee Act (PDUFA) of October 30, 2014 — The NDA was submitted to the … Correction: U.S. FDA Accepts Veloxis’ New Drug Application for Envarsus® for …GlobeNewswire (press release) |
|
FDA Approves Merck’s NOXAFIL® (posaconazole) Injection (18 mg/mL) for …
EIN News (press release) The administration of NOXAFIL with sirolimus, pimozide, quinidine, atorvastatin, lovastatin, simvastatin and ergot alkaloids must be avoided. When administered with NOXAFIL, some drugs such as cyclosporine and tacrolimus required dosage adjustments … |
|
FDA Approves Merck’s NOXAFIL(R) (posaconazole) Injection (18 mg/mL) for …
Wall Street Journal The administration of NOXAFIL with sirolimus, pimozide, quinidine, atorvastatin, lovastatin, simvastatin and ergot alkaloids must be avoided. When administered with NOXAFIL, some drugs such as cyclosporine and tacrolimus required dosage adjustments … |
Drug Discovery & Development |
FDA Approves Merck’s NOXAFIL® (posaconazole) Injection (18 mg/mL) for …
MarketWatch The administration of NOXAFIL with sirolimus, pimozide, quinidine,atorvastatin, lovastatin, simvastatin and ergot alkaloids must be avoided. When administered with NOXAFIL, some drugs such as cyclosporine and tacrolimus required dosage adjustments and … FDA Approves Merck’s NOXAFIL(R) (posaconazole) Injection (18 mg/mL) for …Wall Street Journal |
|
FDA Approves Merck’s NOXAFIL ® (posaconazole) Injection (18 mg/mL) for …
Business Wire (press release) The administration of NOXAFIL with sirolimus, pimozide, quinidine, atorvastatin, lovastatin, simvastatin and ergot alkaloids must be avoided. When administered with NOXAFIL, some drugs such as cyclosporine and tacrolimus required dosage adjustments … |